EMCURE.NS Profit & Loss

Emcure Pharmaceuticals Ltd.

Profit & Loss · 2 years on file (FY2024-25 to FY2025-26) · fetched 2026-08-24 01:34

Line item	FY2024-25	FY2025-26	Source (XBRL element)
Revenue from Operations	₹78.96 Bn	₹92.04 Bn	RevenueFromOperations
Gross Revenue (incl. inter-segment)	N/A	N/A	SegmentRevenueFromOperations
Other Income	₹0.67 Bn	₹0.13 Bn	OtherIncome
Total Income	₹79.63 Bn	₹92.16 Bn	Income
Cost of Materials Consumed	₹15.27 Bn	₹16.93 Bn	CostOfMaterialsConsumed
Purchases of Stock-in-Trade	₹18.83 Bn	₹23.97 Bn	PurchasesOfStockInTrade
Changes in Inventories	₹-2.64 Bn	₹-4.33 Bn	ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade
Employee Benefit Expense	₹14.46 Bn	₹15.52 Bn	EmployeeBenefitExpense
Finance Costs	₹1.76 Bn	₹1.44 Bn	FinanceCosts
Depreciation and Amortisation	₹3.84 Bn	₹4.15 Bn	DepreciationDepletionAndAmortisationExpense
Other Expenses	₹18.29 Bn	₹21.30 Bn	OtherExpenses
Total Expenses	₹69.82 Bn	₹78.98 Bn	Expenses
Profit Before Exceptional Items and Tax	₹9.82 Bn	₹13.18 Bn	ProfitBeforeExceptionalItemsAndTax
Exceptional Items	₹-0.10 Bn	₹-0.31 Bn	ExceptionalItemsBeforeTax
Profit Before Tax	₹9.71 Bn	₹12.87 Bn	ProfitBeforeTax
Tax Expense	₹2.64 Bn	₹3.46 Bn	TaxExpense
Net Profit (incl. minority interest)	₹7.07 Bn	₹9.41 Bn	ProfitLossForPeriod
Net Profit (to shareholders)	₹6.81 Bn	₹9.24 Bn	ProfitOrLossAttributableToOwnersOfParent
Basic EPS	₹36.43	₹48.77	BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations
Diluted EPS	₹36.43	₹48.77	DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations

Every figure above is the exact value of the named XBRL element from EMCURE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).